Zai Lab Limited reported $450M of revenue over the trailing twelve months, +5.1% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $450M (to Q2 2026). Net income: −$188M, trailing twelve months to Q2 2026. Free cash flow: −$140M, trailing twelve months to Q2 2026. Operating margin: −60%, trailing twelve months to Q2 2026.

ZLABZai Lab Limited

Healthcare

$25.01-23% 1Y

$25.01

$16.3052 weeks$34.44

ZLAB as reported

Zai Lab Limited reported $450M of revenue over the trailing twelve months, +5.1% on the year before. 10 reported series are charted on this page, each one as filed.

$450M

Revenue, trailing twelve months · to Q2 2026 · +5.1% against the twelve months before

Net income: −$188M
Net income · −11% year on year · trailing twelve months to Q2 2026
Free cash flow: −$140M
Free cash flow · −24% year on year · trailing twelve months to Q2 2026
Operating margin: −60%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ZLAB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$450M	+5.1%	Q2 2026
Net income	−$188M	−11%	Q2 2026
EPS	−$0.18	−10%	Q2 2026
Gross margin	57%	n/a	Q2 2026
Operating margin	−60%	n/a	Q2 2026
Net margin	−42%	n/a	Q2 2026
ROE	−27%	n/a	Q2 2026
ROA	−17%	n/a	Q2 2026
ROIC	−83%	n/a	Q2 2026
Free cash flow	−$140M	−24%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.